In agreement with our hypothesis, the pharmacological inhibition of CX3CR1 by the administration of the allosteric noncompetitive FKN antagonist AZD8797 accelerated tumor progression (P < 0.05; Fig 2B). The gene discussed is CX3CR1; the disease is neoplasm.